Doc Talk

Children and teens can have difficulty with bladder and bowel incontinence (leaking urine or stool), constipation, pain when using the restroom (dysuria) or pelvic pain. There are myriad reasons why kids have pelvic floor issues. This could be due to pelvic floor dysfunction, muscle imbalance or diet, Join us in a lively discussion with Cook Children’s pediatric pelvic floor therapists Caitlin Smith, MOT, OTR/L, and Kathy Manthuruthil, PT, DPT, PCS, CPST on the many causes and when to refer patients to pediatric pelvic floor rehabilitation/

Join Cook Children’s team of experts on blazing new trails in treating and curing hyperinsulinism (HI) for children across the nation and around the globe. Hear what’s being done to cure more patients and expand treatment most difficult cases.

There is a misconception that palliative means end of life care. But that's not how we think about palliative surgery at all. Palliative surgery is when we're looking at not necessarily curing something, but alleviating something. Cook Children’s Palliative epilepsy neurosurgery explains how kids with intractable epilepsy are getting a better quality of life.

Any surgery can be challenging and come with risks. But when that surgery involves children, it comes with a unique set of things the surgery team has to consider that are very different from adults. Dr. Kanika Bowen-Jallow delves into how those differences impact both the surgical team and patient outcomes. Meet the speaker Meet Dr. Bowen-Jallow Related information Cook Children's Pediatric Surgery Adolescent Bariatric Surgery: Effects of Socioeconomic, Demographic, and Hospital Characteristics on Cost, Length of Stay, and Type of Procedure Performed. - Abstract - Europe PMC A call to action: Multi-disciplinary care and treatment of obesity in pediatrics - PubMed (nih.gov) Wearable Activity Tracking Device Use in an Adolescent Weight Management Clinic: A Randomized Controlled Pilot Trial - PubMed (nih.gov) One Size Does Not Fit All: Sociodemographic Factors Affecting Weight Loss in Adolescents. - Abstract - Europe PMC Cook Children’s Endocrinology REACH Clinic Breaking barriers: Meet the 9th black female pediatric surgeon in the U.S. GMA: Woman makes history as 9th Black female pediatric surgeon in US Cook Children’s community task force leading discussion on suicide prevention and mental health Adverse Childhood Experiences (ACEs) Doctor Groups Ask for Tougher Stance on Kids’ Sugary Drinks They're active, eat healthy … and they have high cholesterol? https://www.checkupnewsroom.com/theyre-active-eat-healthy--and-they-have-high-cholesterol/

Dr. Lisa Vaughan, manager, Cook Children’s Audiology Program takes us on a deep dive into the exciting research, osseointegrated devices and technological advancements, the latest treatments in pediatric audiology, along with the challenges and rewards for children with hearing loss.

Cook Children's pediatric gastroenterologist, Clifton Huang, M.D., shares fascinating insights into the advancing treatments and procedures, including endomicroscopy, that are bringing new hope for children with rare or complicated conditions.

Dr. Scott Perry, Medical Director of Neurosciences and Dr. Christos Papadelis, Director of Neurosciences Research along with Dianna Grado, Clinical Coordinator for Neurosciences Research, explore how breaking research boundaries creates limitless possibilities, paving the way for world-class research – and results once thought impossible for kids and young adults with neurological disorders. Meet the speakers Meet Dr. PerryMeet Dr. PapadelisDianna Grado, RN Related information Jane and John Justin Neurosciences Research Center Clinical Research Adult Genetic Epilepsy Clinic Comprehensive Epilepsy Program Movement Disorders Movement Disorders Clinic Cerebral Palsy Clinic Cook Children’s Neurology Cook Children’s Neurosciences Research Center Dodson Neuro Research Endowment The Arcuate Primary steps for primary care: Sleep disorders in epilepsy and cerebral palsy Infantile Spasms- Primary Steps for Primary Care Staring Spells – Primary Steps for Primary Care Febrile Seizures – Primary Steps for Primary Care The Arcuate – Neuroscience Research Early Identification and Improving Life-Long Outcomes in Cerebral Palsy Patients New-Onset Seizure Clinic Seeks to Decrease Wait Time for Initial Evaluation BE FAST to Recognize the Signs of Pediatric Stroke Pioneering Surgery Disconnects Left Side of Brain to Stop Child’s Daily Seizures Teen Becomes First in North Texas to Undergo Landmark Brain Surgery for Epilepsy Transcript 00:00:11 Host: Hello and welcome to this edition of Doc Talk. We're honored and excited today to be speaking with key researchers at Cook Children's Jane and John Justin Neurosciences Center. We're joined by Dr. Scott Perry, Medical Director of N

With the growing number of pediatric congenital heart patients growing up thanks to ever improving medical care, Dr. Scott Pilgrim takes us inside one of the few programs in the nation that bridges the gap to adult care without missing a beat. Meet the speaker Meet Dr. Pilgrim Related information Cook Children's Adult Congenital Heart Disease Program Adult Congenital Heart Disease Conditions Cook Children's Heart Center Specialty Programs Cook Children’s Heart Center Coming home: nurse returns to Cook Children’s for open heart surgery Diving heart first Heart-to-heart. Mother and daughter share the same cardiologist Transcript 00:00:02 Host Hello and welcome to Cook Children's Doc Talk. Today we're talking with Dr. Scott Pilgrim, who is the medical director of the Adult Congenital Heart Disease program here at Cook Children's. Dr. Pilgrim is board-certified in pediatrics, internal medicine, pediatric cardiology and adult congenital cardiology. Prior to coming to Cook Children's, Dr. Pilgrim founded the adult congenital heart disease program at the Steven and Alexandra Cohen Children's Medical Center in Long Island. Today, under his leadership, the Adult Congenital Heart Disease program at Cook Children's Medical Center has shown tremendous growth with over 500 adult visits every year. Welcome Dr. Pilgrim. 00:00:42 Dr. Pilgrim Thank you. 00:00:43 Host So growing up with a sister who had heart surgery as a child had a major influence in your life, and ultimately led you to your role here at Cook Children's as medical director of the ACHD program, compared to many other cardiac specialties, adult congenital as a specialty is relatively new, can you give us a little history. 00:01:03 Dr. Pilgrim So, as you mentioned, my sister was born with a congenital heart disease. And so growing up with this in my family, it became of interest to me at a very young age. But as a field, congenital heart disease is something that has been around obviously, for several decades, this field of adult congenital heart disease has grown primarily because of the success stories that we've had in pediatric cardiology, namely, the surgical outcomes and the longevity of patients related to improved surgical care, improved surgical technique, you know, recognizing disease, early on fetal diagnosis, and so on and so forth. And so the incidence of congenital heart disease really hasn't changed. But the lifespan of individuals growing up with congenital heart disease has tremendously improved. And so when we think about the growth of adult congenital heart disease in the country, it really has grown out of necessity, because these kids are now growing up and becoming adults. In fact, the number of adults with congenital heart disease now far outweighs the number of children with congenital heart disease in th

Dr. Holly Pacenta, Pacenta takes us into the future of curing and treating pediatric cancer through the use of the patient's own immune system to target the cancer. At the forefront of the technology is CAR T-cell therapy targeting relapsed and refractory B-ALL cells to eradicate cancer with minimal side effects. Meet the speaker Meet Dr. Pacenta Related information Cook Children's Cellular Immunotherapy program Cook Children’s Leukemia and Lymphoma care Cook Children's Oncology program Cook Children's Hematology and Oncology Transcript 00:00:02 Host: Hello and welcome to Cook Children's Doc Talk. Our guest for this episode is pediatric hematologist oncologist Dr. Holly Pacenta. Dr. Pacenta began her career at Children's Hospital Colorado, where she developed her primary interest in new treatments for children with relapsed leukemia, including immunotherapy, cellular therapy and targeted therapy. She has been heavily involved in research, has published several works and received awards and recognition for her work. Today, Dr. Pacenta oversees the Cellular Immunotherapy program at Cook Children's where she and the oncology team are very excited about providing CAR T-cell therapy to patients with relapsed B-cell acute lymphoblastic leukemia, or ALL. Cellular immunotherapy introduces a new era in the treatment of children and young adults here at Cook Children's. Welcome Dr. Pacenta. We are very excited to have you here to talk about this incredible program and CAR T-cell therapy. 00:01:01 Dr. Pacenta: Thank you so much for having me. 00:01:03 Host: Can you start by giving us a little background on the cellular immunotherapy program and an overview of immunotherapy and CAR T-cell therapy? 00:01:11 Dr. Pacenta Sure. So I think first to give an overview of immunotherapy and CAR T-cell therapy, we think at the forefront of the future of curing and treating pediatric cancer is to use, help use the patient's own immune system to target the cancer. So that's what immunotherapy is. Immuno meaning the immune system in therapy meeting treatments, so using the immune system to help treat your own cancer. And then CAR T-cell is a form, kind of a hybrid, of cellular immunotherapy. So we use one of the cells as part of the immune system, the T cells that typically help fight infection, and those get sent to a lab where they're reprogrammed to target the leukemia. So that's CAR T-cell therapy is. Then, our cellular immunotherapy program is a dedicated group of oncologists and stem cell transplant doctors here at Cook Children's along with some supportive services like pharmacy, dieticians, psychologists, etc., that will help provide these types of therapies to our patients. 00:02:13 Host: So KYMRIAH® is the CAR T-cell therapy currently approved for pediatric treatment of children and young adults with refractory or relapsed B-cell ALL, why this particular condition? 00:02:26 Dr. Pacenta: Immunotherapy and cellular therapy are a big interest in pediatric cancer in general. And there has b

Listen Now Preventing adult heart attacks in early childhood? Don Wilson, M.D., explains why it's absolutely within REACH. Children with high cholesterol, especially those who have a genetic cause, such as familial hypercholesterolemia, also know as fH, are at a higher risk for developing premature heart disease, such as heart attack or stroke as they become adults. At the forefront of developing guidelines for lowering this risk, Dr. Wilson details how the Risk Evaluation to Achieve Cardiovascular Heath, or REACH, clinic at Cook Children's is putting those guidelines to work and changing the outcomes for these in the future, and saving the lives of parents today. Meet the speaker Dr. Don Wilson Related InformationRisk Evaluation to Achieve Cardiovascular Health (REACH) Clinic Diabetes Program Endocrinology Program They're Active, Eat Healthy, and Have High Cholesterol-Why? Harper's Story Kids at Risk of Smoke Exposure in Smoke-Free Areas? A Simple Blood Test Could Save Your Child's Life The Unique Risks of Being a Woman with Diabetes Number of Children and Adolescents Who are Obese 10 Times Higher than 40 Years Ago Transcript: 00:00:03 Host: Hello, and welcome to Cook Children's Doc Talk. Today we're talking with Dr. Don Wilson about genetic dyslipidemia, and cardiovascular disease. But first, here's just a little about Dr. Wilson. He is board certified in pediatrics, pediatric endocrinology and clinical lipidology. He is the founder and currently the medical director of Cook Children's REACH program, one of the first cardiovascular risk assessment clinics for children and adolescents in the nation. Dr. Wilson is a fellow of the National Lipid Association and an associate editor for The Journal of Clinical Lipidology and a member of the

Neurosurgeon, Daniel Hansen, M.D. shines a light on this barrier breaking approach to epilepsy surgery. Using an endoscopic method to disconnect the left and right brain, this minimally invasive procedure has the same chance of seizure freedom post-surgery as traditional callosotomy, while reducing operating time and recovery time. Meet the speaker Meet Dr. Hansen Related information Pioneering Surgery Disconnects Left Side of Brain To Stop Child’s Daily Seizures Boy Receives Pioneering Surgery to Stop Child's Daily Seizures The Pioneer: Child Becomes First Patient in Trailblazing Endoscopic Surgery that Disconnects Part of His Brain to Stop Daily Seizures Cook Children's Patient Becomes First in North Texas Implanted with Smart Device to Control Seizures Teen with Cancer Walks a Marathon During Hospital Stays Cook Children's Neurosurgery Cook Children's Neonatal Neurology and Neurosurgery Comprehensive Epilepsy Program Jane and John Justin Neurosciences Center Transcript 00:00:03 Host: Hello and welcome to Cook Children's Doc Talk. Our guest for this episode is pediatric neurosurgeon Dr. Daniel Hansen. Dr. Hansen sees and treats children for the whole range of pediatric neurosurgical issues, and has special interest in minimally invasive surgery, endoscopic surgery, tumors and epilepsy. He works closely with the neuro-oncology and epileptology teams to provide cutting edge patient-centered treatment, using the most up to date information and treatment options. Dr. Hansen is the first neurosurgeon at Cook Children's and one of only two in the state of Texas to perform an endoscopic corpus callosotomy and endoscopic surgery on the corpus callosum that separates the right and left sides of the brain for children with certain types of intractable epilepsy or severe seizures. He's also one of the first pediatric surgeons in the nation to perform the endoscopic approach. Welcome, Dr. Hansen. 00:00:58 Dr. Hansen: Thank you. 00:00:58 Host: I want to sta

Listen NowDr. Steve Muyskens, Medical Director, Cardiac MRI, 3-D aPPROaCH Lab, Cook Children's, takes us into the world of 3D heart printing. It’s a fascinating journey into how this advancing technology can take the guess work out of pediatric heart surgery, helping more young patients can thrive into adulthood. Dr. Steve Muyskens Related InformationCook Children's 3D aPPROaCH LabCardiac Magnetic Resonance ImagingCook Children's Cardiothoracic Surgery programCook Children's Endowed Chair ProgramCook Children's Heart Center Transcript 00:00:02 Host: Hello and welcome to Cook Children's Doc Talk. Today we welcome Dr. Steve Muyskens, medical director of the Cardiac MRI program here at Cook Children's in Fort Worth, Texas. Dr. Muyskens, is an endowed chair supporting the expansion of our CMRI program and its diagnostic uses. He has since established the three-dimensional lab for the planning and printing of congenital heart disease, which uses advanced technology to support presurgical planning and family education for patients with complex heart conditions. He is our expert on this subject. So thank you for being with us today, Dr. Muyskens/ 00:00:36 Dr. Muyskens: Thank you very much for the invitation. 00:00:38 Host: So what exactly is a 3D model? And what is the process for creating that model? 00:00:44 Dr. Muyskens So I think the important part is to kind of start with the patient. There are conditions with varying degrees of complexity that our current diagnostic modalities fall short in some manner. So those patients have long been difficult to manage. We started realizing that we can use technology like 3D printing and virtual 3D animation to help us better understand their condition. So when we identify that patient, whether it be an older patient who has already had some surgeries, or a newborn who has a very complex heart, who we're hoping to do an initial palliation, or surgical repair on, the first thing we decide is, what is the best modality to obtain the information that we would need to then use that technology. The two most commonly used technologies would be MRI, or cardiac CT. You can use rotational angiography in the cath lab, but that's much less commonly used. Once we have that selection made, the data is obtained by us obtaining a typical CT scan or a typical cardiac MRI. But then that data, which is in a raw form called DICOM. DICOM data is then moved to specialized software. And from there, I take that data, and we segment it is the term we use, basically manipulate that data and create a virtual model, essentially, from that information. That model can then be viewed either in the virtual space, so on a typical computer that you would flip around, but then again, you're still only in two dimensions you're looking at in a screen. So then typically, we move on to a 3D printing of that data. So the typical segmentation portion, or manipulation of the data, can vary from anywhere to two to 24 hours of time, depending on the complexity of the model. An

Listen Now Dr. Sibo Zhao takes us on an exploration of new, novel, treatments and research in pediatric neuro-oncology. She also brings into focus the added complexities in brain tumors in children and how those complexities both challenge and benefit what physicians are learning in order to improve treatment. Meet Dr. Zhao Related information Neuro-Oncology Oncology Fertility Preservation Life After Cancer Hematology and Oncology Clinical Research Transcript 00:00:03 Host Hello and welcome to Cook Children's Doc Talk. Treating brain and spinal tumors can be extremely challenging, especially in children. But there have been many breakthroughs in pediatric neuro oncology with more new advancements on the horizon. Today we're talking with Dr. Sibo Zhao, about what's happening in this field. Dr. Zhao is medical director of Cook Children's pediatric Neuro-Oncology Program. She is actively involved in research here at Cook Children's and has written extensively on this subject. Not only is she dedicated to advancing treatment, she is also passionate about how care is delivered to patients and their families as they go through treatment. Dr. Zhao, welcome. We appreciate your taking the time to talk with us. 00:00:46 Dr. Zhao Thank you for having me today. 00:00:48 Host So first off, can you give a little history on yourself? What drew you to the practice of pediatric neuro-oncology? 00:00:57 Dr. Zhao Well Jan, I think throughout my medical trainings, I feel like I've always been drawn to help the vulnerable patient population. You know, that's kind of how I chose pediatrics in the first place, because I felt like the kids, you know, they can't advocate for themselves, they needed more help. And then during residency, oncology would be something that would feel rewarding, because again, those are the kids that need more, and I was drawn to that. So I went to the hemonc and I kinda was wide open thinking like, okay, I want to do oncology, and really sure what kind of tumors are necessarily even needed to pick one. But during fellowship, and during just kind of my early career, I think the brain tumor patients just always kind of tapped on my heart a little bit. And I wanted to do a little bit more for them. And also, the other main thing is that pediatric neuro oncology has not really advanced as fast or as quickly as some of the other types of pediatric malignancies such as you know, leukemia patient outcomes, I felt like there was a need. And this may be something that if I went into that field, I could change that. 00:02:10 Host So why did you choose the program at Cook Children's? And how does your research background fit in with your role here? 00:02:16 Dr. Zhao So I spent several years at Texas Children's Hospital first as a trainee and then became a faculty, I honestly didn't really think I would like

Listen Now As more young people survive cancer, the issue of fertility preservation is front and center. Dr. Karen Albritton and her team explore the challenges of preserving fertility in children, teens and young adults undergoing cancer treatment and the latest breakthroughs in oncofertility that are delivering promise for the future.Dr. Karen Albritton Related InformtationOncofertilityAdolescent/Young Adult (AYA) ProgramLife After CancerOncologyHematology and OncologyHematology and Oncology ResearchFort Worth Adolescent and Young Adult Onoclogy Coalition Transcript 00:00:02 Host: Hello and welcome to Cook Children's Doc Talk. A while back we talked with Dr. Karen Albritton the medical director of Cook Children’s adolescent and young adult program in the Hematology and Oncology Center, and she oversees the Oncofertility Program. We also spoke with Olivia Prebus who was instrumental in developing the role of fertility navigator for the program. More recently, we talked with Toni Leavitt who we’ll be introducing later in the program. Toni is the current fertility navigator and we'll be sharing updates about the Oncofertility Program. Dr. Albritton is trained in both pediatric and medical oncology and specializes in the care of adolescents and young adults with cancer. She recognizes the unique needs of these young patients and the challenging decisions they face about day to day living that most people take for granted. One of the biggest and often overlooked as how fertility is impacted by the cancer treatment they receive. As an active advocate for AYA cancer patients, doctor Albritton was instrumental in founding the AYA program here at Cook Children’s as well as the Fort Worth AYA Oncology Coalition, which provides resources for cancer patients and survivors, health professionals and community members. The Fort Worth AYA Oncology Coalition launched the first community supported AYA oncology inpatient unit in the nation and offers young adults diagnosed with cancer age relevant resources and specialized care designed to improve their lives before, during, and after cancer. It is through her experience with AYAs that doctor Albritton has seen a need to consider fertility as part of all pediatric cancer care and establishing the oncofertility program here at Cook Children’s. Welcome. 00:01:48 Dr. Albritton: Thanks for having us. 00:01:51 Host: So let me start by asking what oncofertility is and why it's important? 00:01:55 Dr. Albritton: Oncofertility is a relatively new term in the cancer world and it is a combination of 2 fields, reproductive endocrinology which deals with fertility for people with and without cancer for many different reasons who are seeking to either preserve their fertility or attempt to have children to use fertility methods to have biologic children, and many years ago it was realized that cancer patients have their fertility affected by the cancer treatments and that these 2 fields cam

Listen Now Dr. Clarissa Johnson peels back the curtain on the unique challenges for pediatric patients with sickle cell disease, the risks involved with transitioning to adult care, and clinical trials and research that offer hope for a brighter future here and around the world.Meet the speakerDr. Clarissa Johnson Related InformationSickle Cell DiseaseHematologyHematology and OncologyClinical Research Transcript00:00:04 Host: Hello and welcome to Cook Children’s Doc Talk. We're here today talking with Dr. Clarissa Johnson about sickle cell disease and the advanced treatments and research she leads here at Cook Children’s. Dr. Johnson is a member of Cook Children’s hematology and oncology team and the lead physician of the Sickle Cell program. She is actively involved in research Cook Children’s and has written extensively on the unique medical care needs an infection risks of children with sickle cell disease. In addition to her work at Cook Children’s Dr. Johnson has also made many medical mission trips to hospitals and clinics in Nigeria, Ethiopia and Eritrea. Those trips help to provide her with an even more intense drive to find a cure and she puts that drive into action every day in the compassionate care she provides to patients and families at Cook Children’s. Dr. Johnson, welcome and thank you for being here today. 00:00:55 Dr. Johnson: Thank you for having me. 00:00:58 Host: Can you start off by telling us a little about Cook Children's Sickle Cell Program? 00:01:02 Dr. Johnson: The program at Cook Children’s was established many years ago when the hematology oncology division was started at this institution by Dr. Paul Bowman. It has evolved over the years and by the time that I started working here in 2009 it was a well established program. I became the program director a short time after that and since that time have worked really to bring more research trials to our patient population and to have a cohesive management of care. Our team includes a nurse, a therapist. a social worker, and then three physicians who primarily take care of the patients here, of which I am one. We follow about four hundred patients from across the state of Texas, so that includes patients in West Texas, north of us in the Wichita Falls area, now Tyler in East Texas, south of us in Waco and then of course here in the immediate DFW area, which is probably where most of our patients come from. 00:02:01 Host: Can you tell us maybe a little bit about the types of advanced research trials we’re part of. 00:02:06 Dr. Johnson: Over the years Cook Children’s has been invited to participate in several trials, including trials on iron chelation in children, that is something that we use in children with sickle cell who need transfusion therapy and overtime may have iron levels build up in your body because of that, so we participate in that trial. We have collaborated with the group over in Dallas with some trials to look at the effect of something called a patent foramen ovale, or a small hole in the heart in terms of its influence on the

Listen Now Dr. Paul Thornton and Dr. Blake Palmer lead a lively round-table discussion on reaching clinical excellence through exceptional interdisciplinary care for patients and families. Dr. Paul ThorntonDr. Blake PalmerCortney Wolfe-Christensen PhDEmily Haddad LCSW Related InformationCongenital Adrenal Hyperplasia (CAH)Treating Congenital Adrenal HyperplasiaCook Children's Endocrinology DepartmentCook Children's Pediatric Urology Department Transcript 00:00:02 Host: Hello and welcome to Cook Children's Doc Talk. Today we're talking about congenital adrenal hyperplasia. Cook Children's is designated by the Cares Foundation as a Center of Excellence for Congenital Adrenal Hyperplasia. Joining us are members of the team, Dr. Paul Thornton, Medical Director, Endocrine and Diabetes Program, Dr. Blake Palmer, Medical Director Pediatric Urology and Surgical Director Kidney Transplantation. Dr Cortney Wolfe Christiansen, clinical child psychologist, and Emily Haddad, a licensed clinical therapist and social worker. Welcome to all of you. 00:00:39 All: Thanks for being here. Thank you for having us, happy to be here. 00:00:43 Host: Congenital adrenal hyperplasia or CAH, is one of the most common inherited metabolic disorders. We know that there are two forms of CAH, classic and non classic. Non classic is a mild form of CAH and fairly asymptomatic, while classic CAH is very severe and often life threatening. From birth, the classic form of CAH affects approximately one in 15,000 babies born each year. While we can touch briefly on the non classic form, I'd really like to focus on the classic form of CAH and the unique challenges faced when caring for children with this disease. Dr Thorton, as the medical director of this program can you take us through an overview of CAH? 00:01:25 Dr. Thornton: Yes, congenital adrenal hyperplasia CAH as we like to abbreviate it, is a condition in which there is an enzyme deficiency in the adrenal glands and as a result we get a deficiency in some of the most critical hormones in the body for example cortisol with in excess of the sex steriods, particularly the androgens being produced. And why this is very important is that cortisol is essential for life and in times of critical illness our bodies make more cortisol in order to help us survive and children with CAH are unable to do this and hence they can have life threatening adrenal crises which can be manifested as hypotension and hypoglycemia and can be critically dangerous. So with classical congenital adrenal hyperplasia there are 2 forms. there are those who are missing the cortisol and that would be called simple virilizing, and then 75 percent of the kids are missing both cortisol and aldosterone which is called salt wasting CAH, and that is by far the most dangerous of the 2 conditions. 00:02:31 Host: Dr Tho

Listen NowDr. Heym gives insight into Total Therapy XVII and why this all important breakthrough in precision medicine and targeted treatment approaches offers the promise of more cures for acute lymphoblastic leukemia and acute lymphoblastic lymphoma patients. Kenneth Heym, M.D. Related Information:About the Total Therapy Study XVII at Cook Children'sCook Children's Hematology and Oncology CenterCook Children's Oncology ProgramCook Children's Leukemia and LymphomaCook Children's Hematology and Oncology Clinical Research Transcript: 00:00:01 Host: Hello and welcome to Cook Children’s Doc Talk. We're here today with Dr. Kenneth Heym, Medical Director of Cook Children’s Oncology Program. Dr. Heym specializes in the care of children with childhood cancers as well as being the medical director of oncology. Dr. Heym is also very actively involved in research focusing mainly on leukemia and lymphoma and has published several important works on the subject. Dr. Heym, thank you for joining us today to talk about Total Therapy Seventeen, the upcoming clinical trial for children with acute lymphoblastic leukemia or acute lymphoblastic lymphoma. 00:00:38 Dr. Heym: Thank you for having me here and it's my pleasure to be able to discuss this exciting work that's going to be something we can be a big part of here at Cook Children's. 00:00:45 Host: So can you start by giving us an overview of the Total Therapy Seventeen clinical trial. 00:00:51 Dr. Heym: So acute lymphoblastic leukemia is the most common disease that we treat in childhood cancer. It has gone over the years from a uniformly fatal disease to one in which the vast majority of children will not only be cured of their disease but will go on to have the rest of their life just as before. So Total Therapy Seventeen is the upcoming trial for newly diagnosed patients with acute lymphoblastic leukemia, It is through the St Jude Children's Research Hospital in Memphis Tennessee, now, we have been honored to have an ongoing relationship with St Jude for probably the past twenty years. We participated in other clinical trials with them, We were actually the only institution in the world to participate in the Total Fifteen acute lymphoblastic leukemia protocols so we were the only other hospital that participated in an up front newly diagnosed trial for children with ALL with St Jude. Total Seventeen is really going to be a summary of all that we've learned about leukemia in the last decades really trying to maximize not only the existing therapies that we have for childhood leukemia but also incorporating so much new technology and some of the really cutting edge therapies that are being used, the goal being to cure as many children as possible obviously but also to try to minimize the side effects which can occur both during therapy and long term later in life. The goal is really to try to provide individualized care to each patient. 00:02:15 Host: S

Listen Now Go inside the challenging world of pediatric renal transplant with Dr. Robert Gillespie and Dr. Blake Palmer and explore how their unique approach goes beyond traditional care. Robert Gillespie, M.D.Blake Palmer, M.D. Related Information:Cook Children's Nephrology and DialysisCook Children's Renal Transplant Program Transcipt: 00:00:01 Host: Today we're talking with doctor Robert Gillespie and doctor Blake Palmer of Cook Children’s Renal Transplant Program. It's very busy in the Child Life Zone today so you may hear a little background noise. And before we get started just a little background on our guests. 00:00:16 Dr. Gillespie is the medical director for nephrology and kidney transplantation and Dr. Palmer is the medical director of urology here at Cook Children’s. Doctor Gillespie earned his medical degree from the University of Texas Medical Branch at Galveston and completed his fellowship at University of Washington Seattle Children’s. Dr. Gillespie has written extensively for peer reviewed medical publications and has given many presentations to medical groups around the country. His professional activities include international outreach programs development of computer based tools for nephrologists and he has actively participated in numerous research studies.In the summers he serves as a camp doctor for Camp Reynal a summer camp for children with kidney diseases. 00:01:01 Dr. Palmer earned his medical degree from University of Oklahoma and completed both the research and clinic fellow at University of Oklahoma department of pediatric urology. He is board certified in urology with a subspecialty certification in pediatric urology. His work has been published in multiple peer reviewed journals and he's a nationally recognized presenter and a member of the American Urology Association, American Academy of Pediatrics section of pediatric urology, Society of Pediatric Urology, American Academy of Pediatric Urologists, Society of Fetal Urology, and the American College of Surgeons. He has special certification by the American College of Surgeons in fundamentals of laparoscopic surgery. 00:01:45 Welcome, you are both clearly very busy so thank you for sitting with us today. 00:01:48 Dr. Palmer: Our pleasure. 00:01:49 Dr. Gillespie: Yeah thank you. 00:01:50 Host: So, doctor Palmer, for over a quarter of a century Cook Children’s kidney transplant program has been breaking ground in kidney transplants and is currently the second largest renal transplant program in the state serving not only children in Texas but in surrounding states as well. The program is also a recognized center of excellence by Optum and UnitedHealth but one of the really unique advantages of this program is the team approach between urology and nephrology can you tell us a bit about your partnership and how it benefits pediatric patients. 00:02:22 Dr. Palmer: So I'm happy to talk about our pro

Listen NowDr. Stephanie Acord discusses how early identification and new diagnostic methods and therapies for children with mild to severe cerbral palsyare helping to improve life-long outcomes. Dr. Stephanie Acord Related Information:Cook Children's Neurosciences Movement Disorders Research Cook Children's Neurosciences Transcript: 00:00:02 Host: Welcome to Doc Talk, today we're talking with pediatric neurologist Dr. Stephanie Acord. Dr. Acord sees and treats children with cerebral palsy and is a member of Cook Children’s Movement Disorders Program. She also works closely with the neurosurgery eileptology, physiatry, and stroke teams here at Cook Children’s to provide patients and their families with the most up to date information and treatment options. Welcome Dr. Acord. 00:00:27 Dr. Acord: Thank you. Glad to be here. 00:00:31 Host: So I'd like to start off with a little background about you how did you choose neurology and in particular movement disorders and cerebral palsy? 00:00:38 Dr. Acord: I don't think there is actually a patient that I can recall that steered me in the direction of neurology it's more of that type of field of medicine that neurology is a lot of times people think of it more as that kind of like putting together pieces of a puzzle, and I think that's why many people actually shy away from neurology. But to me that's the challenge that is intriguing, and very interesting to me. 00:01:11 Dr. Acord: My first exposure with movement disorders and cerebral palsy actually came here at Cook Children’s. I was in the middle of doing a child neurology rotation at the university of Kentucky and I became very interested in reached out actually to Cook Children’s and got a rotation set up here in between my second and third year of medical school. 00:01:21 Dr. Acord: During that rotation I spent a good portion of time with doctor Warren Marks and Fernando Acosta who really showed me the ropes as maybe disorders. 00:01:31 Dr. Acord: I think one of the unique things about Cook Children’s is that here we have several movement disorder specialist whereas many other places in the country that actually don't have any let alone several 00:01:41 Host: Can you tell us a little about the Cerebral Palsy Program here at Cook Children’s? 00:01:48 Dr. Acord: Cerebral Palsy clinic here at Cook Children’s is a multidisciplinary team approach in which includes the neurologist, the physiatrist, the orthopedic surgeons, neurosurgeons the therapists that are inovolved as well as the orthotics and prosthetics team. The nice thing about having a multidisciplinary team clinic is that you can have several providers looking at a patient at one particular time and all come together in terms of what do they feel like is the best treatment option for the pa

Listen nowDr. Kelly Vallance takes us through the most advanced and promising targeted therapy research and clinical trials available to pediatric cancer patients. She explores how this research is leading to higher response rates, less toxicities, more cures and the hope for a long and happy future for babies, children and young adults with rare forms of cancer. Dr. Kelly Vallance Related InformationMore about Pediatric MATCHCook Children's Solid Tumor ProgramCook Children's Hematology and Oncology Clinical Research

Listen NowDr. Marcela Torres and Dr. Fernanco Acosta, Jr. take us on a deep dive into the causes of pediatric stroke and how their unique B.E.F.A.S.T. approach is improving awareness, diagnosis, treatment and risk of recurrence. It’s a life changing journey for provider, families and especially for children. Dr. Marcela TorresDr. Fernando Acosta, Jr. Related InformationMore on stroke and thrombosisCook Children's Stroke and Thrombosis ProgramCutting-edge imaging to improve pediatric stroke careGet the B.E. F.A.S.T. poster

Listen NowDr. Marcela Torres and Dr. Fernanco Acosta, Jr. take us on a deep dive into the causes of pediatric stroke and how their unique B.E.F.A.S.T. approach is improving awareness, diagnosis, treatment and risk of recurrence. It’s a life changing journey for provider, families and especially for children. Dr. Marcela TorresDr. Fernando Acosta, Jr. Related InformationMore on stroke and thrombosisCook Children's Stroke and Thrombosis ProgramCutting-edge imaging to improve pediatric stroke careGet the B.E. F.A.S.T. poster

Listen NowDr. Timothy McCavit reveals incredible discoveries taking place in the world of hematology and how the latest clinical research in hemophilia is developing transformative treatments that are opening the doors to a new era not only for how patients are cared for, but for the future that awaits them. Dr. Timothy McCavit Related InformationCook Children's Hemophilia CenterCook Children's Hematology and Oncology CenterCook Children's Hematology and Oncology Clinical Research

Listen NowRenowned neurologist Scott Perry M.D. takes us into the rare world of Dravet Syndrome patients and the exciting new treatments available now and on the horizon. Also, peek into the wide range of research, medications that are making a difference in seizures. He also does a deep dive into current research methods, including how zebra fish are helping to find more medications that work. Dr. M. Scott Perry Related InformationMore on Dravet SyndromeCook Children's Comprehensive Epilepsy ProgramCook Children's NeurosciencesThe Arcuate